Dexycu (dexamethasone intraocular injection) / EyePoint Pharma, Ocumension Therap  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Dexycu (dexamethasone intraocular injection) / EyePoint Pharma, Ocumension Therap
NCT01048593: Efficacy and Safety Study of IBI-10090 in Patients Undergoing Cataract Surgery

Terminated
2
6
US
IBI-10090
ICON Bioscience Inc
Inflammatory Reaction Due to Ocular Lens Prosthesis
05/10
06/10
NCT01214174: Efficacy and Safety Study of IBI-10090 in Cataract Surgery Patients

Terminated
2
42
US
IBI-10090
ICON Bioscience Inc
Ocular Inflammation
05/12
05/12
NCT01606735: Efficacy and Safety of IBI-10090 in Ocular Surgery Patients

Completed
2
172
US
IBI-10090
ICON Bioscience Inc
Inflammation Associated With Cataract Surgery
03/13
03/13
SELVEDge, NCT05530421: Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma

Recruiting
2
33
US
Selinexor, Xpovio, Venetoclax, Venclexta, Venclyxto, Dexamethasone, Decadron, Ozurdex, Dexycu
University of Miami, Karyopharm Therapeutics Inc
Relapsed and Refractory Multiple Myeloma
03/26
03/28

Download Options